These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 31236941)
21. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. Maciocia P; Badat M; Cheesman S; D'Sa S; Joshi R; Lambert J; Mohamedbhai S; Pule M; Linch D; Ardeshna K Br J Haematol; 2016 Feb; 172(4):545-53. PubMed ID: 26684148 [TBL] [Abstract][Full Text] [Related]
22. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429 [TBL] [Abstract][Full Text] [Related]
23. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Holte H; Leppä S; Björkholm M; Fluge O; Jyrkkiö S; Delabie J; Sundström C; Karjalainen-Lindsberg ML; Erlanson M; Kolstad A; Fosså A; Ostenstad B; Löfvenberg E; Nordström M; Janes R; Pedersen LM; Anderson H; Jerkeman M; Eriksson M Ann Oncol; 2013 May; 24(5):1385-92. PubMed ID: 23247661 [TBL] [Abstract][Full Text] [Related]
24. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633 [TBL] [Abstract][Full Text] [Related]
25. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Damaj G; Ivanoff S; Coso D; Ysaebert L; Choquet S; Houillier C; Parcelier A; Abarah W; Marjanovic Z; Gressin R; Garidi R; Diouf M; Gac AC; Dupuis J; Troussard X; Morschhauseur F; Ghesquières H; Soussain C; Haematologica; 2015 Sep; 100(9):1199-206. PubMed ID: 26185174 [TBL] [Abstract][Full Text] [Related]
26. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228 [TBL] [Abstract][Full Text] [Related]
27. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102 [TBL] [Abstract][Full Text] [Related]
28. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758 [TBL] [Abstract][Full Text] [Related]
29. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma. Yoo KH; Lee JY; Lim SH; Ko YH; Kim SJ; Kim WS Acta Haematol; 2015; 133(2):179-82. PubMed ID: 25323539 [TBL] [Abstract][Full Text] [Related]
30. Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy. Chan CY; Ou CW; Chang H; Kuo MC; Lin TL; Hung YS; Wu JH; Shih LY; Kao HW J Formos Med Assoc; 2024 Oct; 123(10):1078-1086. PubMed ID: 38296697 [TBL] [Abstract][Full Text] [Related]
31. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989 [TBL] [Abstract][Full Text] [Related]
32. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307 [TBL] [Abstract][Full Text] [Related]
33. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058 [TBL] [Abstract][Full Text] [Related]
34. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement. Steinhardt MJ; Krummenast FC; Rosenwald A; Gerhard-Hartmann E; Heidemeier A; Einsele H; Topp MS; Duell J J Cancer Res Clin Oncol; 2022 Jan; 148(1):205-214. PubMed ID: 34085097 [TBL] [Abstract][Full Text] [Related]
35. High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement. Umino K; Fujiwara SI; Sato K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Hatano K; Okazuka K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y Acta Haematol; 2017; 137(2):93-99. PubMed ID: 28118621 [TBL] [Abstract][Full Text] [Related]
36. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Avilés A; Jesús Nambo M; Neri N Med Oncol; 2013 Jun; 30(2):520. PubMed ID: 23456620 [TBL] [Abstract][Full Text] [Related]
37. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related]
39. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. Kaji FA; Martinez-Calle N; Bishton MJ; Figueroa R; Adlington J; O'Donoghue M; Smith S; Byrne P; Paine S; Sovani V; Auer D; James E; Bessell EM; Grainge MJ; Fox CP Br J Haematol; 2021 Nov; 195(4):561-570. PubMed ID: 34368948 [TBL] [Abstract][Full Text] [Related]
40. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]